The AKT1 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 parental line, in which the AKT1 gene has been disrupted to create a heterogeneous loss-of-function model. This approach circumvents clonal variation, providing a pooled representation of AKT1-disrupted cells suitable for robust population-level studies.
The A2780 cell line is an extensively characterized model of high-grade serous ovarian carcinoma, originally established from a tumor sample of an untreated patient diagnosed with ovarian endometrioid adenocarcinoma. These cells retain key oncogenic pathways and are widely employed in functional genomics and drug discovery research targeting this aggressive cancer subtype.
AKT1 encodes a serine/threonine kinase that serves as a central hub in the PI3K-AKT signaling network. Upon growth factor stimulation, receptor tyrosine kinases such as EGFR and IGF1R activate PI3K, generating PIP3 at the plasma membrane. PDK1 and mTORC2 then phosphorylate AKT1 at Thr308 and Ser473, respectively, leading to its full activation. Active AKT1 phosphorylates a broad array of downstream substrates, including mTORC1 (via TSC2 and PRAS40), GSK-3??, FOXO transcription factors, BAD, caspase-9, S6K, and 4E-BP1, thereby driving cell cycle progression, inhibiting apoptosis, and promoting protein synthesis and metabolic reprogramming. This signaling cascade is negatively regulated by the tumor suppressor PTEN, which dephosphorylates PIP3, and is fine-tuned through interactions with HSP90, integrin-linked kinase (ILK), and the p85 regulatory subunits of PI3K.
In high-grade serous ovarian carcinoma, AKT1 hyperactivation frequently results from PTEN deletion, PIK3CA amplification, or upstream receptor overexpression, contributing to uncontrolled proliferation and chemoresistance. The A2780 AKT1 knockout model thus offers a disease-relevant platform to dissect how loss of this kinase reshapes downstream signaling, metabolic dependencies, and apoptotic thresholds. Additionally, it facilitates investigation into adaptive pathway rewiring following AKT inhibition, providing insights for the development of rational combination therapies.
Researchers can employ this polyclonal knockout pool in diverse experimental workflows: Western blotting and RT-qPCR verify AKT1 ablation and assess phosphorylation status of key substrates such as GSK-3?? and S6K; MTT or CCK8 assays quantify proliferation changes; Annexin V/PI staining monitors apoptosis; and transwell assays evaluate migration and invasion. The cells are also suited for drug sensitivity profiling with AKT inhibitors like MK-2206, and phospho-kinase arrays reveal compensatory signaling alterations. Furthermore, this model supports synthetic lethal screening to identify genes that become essential only upon AKT1 loss and serves as a control for isoform-specific studies of AKT1, AKT2, and AKT3. For further information, please contact Ascent Research.
